The BET bromodomain inhibitor OTX015 shows synergy with several anticancer agents in preclinical models of mantle cell lymphoma (MCL) and multiple myeloma (MM)

被引：0
|
作者：
Bernasconi, E. [1 ]
Tarantelli, C. [1 ]
Gaudio, E. [1 ]
Kwee, I. [1 ]
Stathis, A. [2 ]
Riveiro, E. [3 ]
Herait, P. [4 ]
Cvitkovic, E. [4 ]
Zucca, E. [2 ]
Bertoni, F. [1 ]
机构：
[1] IOR, Lymphoma & Genom Res Program, Bellinzona, Switzerland
[2] Oncol Inst Southern Switzerland IOSI, Bellinzona, Switzerland
[3] Oncol Therapeut Dev, Clichy, France
[4] Oncoethix, Lausanne, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70694-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
568
引用
收藏
页码：184 / 184
页数：1
相关论文
共 13 条
  • [1] The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma
    Gu, Jie
    Song, Sha
    Han, Huiying
    Xu, Hongxia
    Fan, Gao
    Qian, Chen'ao
    Qiu, Yingchun
    Zhou, Wenqi
    Zhuang, Wenzhuo
    Li, Bingzong
    [J]. MOLECULAR PHARMACEUTICS, 2018, 15 (11) : 5387 - 5396
  • [2] The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma
    Bernasconi, Elena
    Tarantelli, Chiara
    Gaudio, Eugenio
    Kwee, Ivo
    Rinaldi, Andrea
    Cascione, Luciano
    Stathis, Anastasios
    Riveiro, Maria Eugenia
    Zucca, Emanuele
    Bertoni, Francesco
    [J]. BLOOD, 2014, 124 (21)
  • [3] OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma
    Todaro, Maria
    Boi, Michela
    Vurchio, Valentina
    Ercole, Elisabetta
    Machiorlatti, Rodolfo
    Messana, Katia
    Landra, Indira
    Urigu, Susanna
    Aliberti, Sabrina
    Riveiro, Eugenia
    Bertoni, Francesco
    Inghirami, Giorgio
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [4] The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
    Boi, Michela
    Gaudio, Eugenio
    Bonetti, Paola
    Kwee, Ivo
    Bernasconi, Elena
    Tarantelli, Chiara
    Rinaldi, Andrea
    Testoni, Monica
    Cascione, Luciano
    Ponzoni, Maurilio
    Mensah, Afua Adjeiwaa
    Stathis, Anastasios
    Stussi, Georg
    Riveiro, Maria Eugenia
    Herait, Patrice
    Inghirami, Giorgio
    Cvitkovic, Esteban
    Zucca, Emanuele
    Bertoni, Francesco
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1628 - 1638
  • [5] Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma
    Gaudio, Eugenio
    Tarantelli, Chiara
    Ponzoni, Maurilio
    Odore, Elodie
    Rezai, Keyvan
    Bernasconi, Elena
    Cascione, Luciano
    Rinaldi, Andrea
    Stathis, Anastasios
    Riveiro, Eugenia
    Cvitkovic, Esteban
    Zucca, Emanuele
    Bertoni, Francesco
    [J]. ONCOTARGET, 2016, 7 (36) : 58142 - 58147
  • [6] BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma
    Cascione, Luciano
    Gaudio, Eugenio
    Bernasconi, Elena
    Tarantelli, Chiara
    Rinaldi, Andrea
    Testoni, Monica
    Bomben, Riccardo
    Gattei, Valter
    Kwee, Ivo
    Stathis, Anastasios
    Riveiro, Maria Eugenia
    Zucca, Emanuele
    Bertoni, Francesco
    [J]. BLOOD, 2014, 124 (21)
  • [7] OTX015, a BET-bromodomain (BET-BRD) inhibitor, potentiates the in vitro effects of chemotherapy drugs and targeted agents in human leukemic cell lines
    Astorgues-Xerri, L.
    Canet-Jourdan, C.
    Bekradda, M.
    Cvitkovic, E.
    Herait, P.
    Raymond, E.
    Riveiro, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 183 - 183
  • [8] Gene expression profile of OTX015, a BET bromodomain inhibitor, in preclinical models of non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) models
    Riveiro, Maria Eugenia
    Kwee, Ivo
    Astorgues-Xerri, Lucile
    Bekradda, Mohamed
    Vazquez, Ramiro
    Rinaldi, Andrea
    Cvitkovic, Esteban
    Bertoni, Francesco
    [J]. CANCER RESEARCH, 2015, 75
  • [9] Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
    Amorim, Sandy
    Stathis, Anastasios
    Gleeson, Mary
    Iyengar, Sunil
    Magarotto, Valeria
    Leleu, Xavier
    Morschhauser, Franck
    Karlin, Lionel
    Broussais, Florence
    Rezai, Keyvan
    Herait, Patrice
    Kahatt, Carmen
    Lokiec, Francois
    Salles, Gilles
    Facon, Thierry
    Palumbo, Antonio
    Cunningham, David
    Zucca, Emanuele
    Thieblemont, Catherine
    [J]. LANCET HAEMATOLOGY, 2016, 3 (04): : E196 - E204
  • [10] Preclinical Evaluation of the BET-Bromodomain (BET-BRD) Inhibitor OTX015 in Leukemia Cell Lines Harboring the JAK2 V617F Mutation
    Riveiro, Maria Eugenia
    Astorgues-Xerri, Lucile
    Canet-jourdan, Charlotte
    Bekradda, Mohamed
    Cvitkovic, Esteban
    Herait, Patrice
    Raymond, Eric
    [J]. BLOOD, 2014, 124 (21)
12